{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:31:15Z","timestamp":1787761875806,"version":"build-2784847793"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG","award":["NCT02662985"],"award-info":[{"award-number":["NCT02662985"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active PsA using Power Doppler ultrasound.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The randomized, placebo-controlled, Phase III ULTIMATE study enrolled PsA patients with active ultrasound synovitis and clinical synovitis and enthesitis having an inadequate response to conventional DMARDs and na\u00efve to biologic DMARDs. Patients were randomly assigned to receive either weekly subcutaneous secukinumab (300 or 150\u2009mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome was the mean change in the ultrasound Global EULAR and OMERACT Synovitis Score (GLOESS) from baseline to week 12. Key secondary endpoints included ACR 20 and 50 responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 166 patients enrolled, 97% completed 12\u2009weeks of treatment (secukinumab, 99%; placebo, 95%). The primary end point was met, and the adjusted mean change in GLOESS was higher with secukinumab than placebo [\u22129 (0.9) vs \u22126 (0.9), difference (95% CI): \u22123 (\u22126, \u22121); one-sided P=0.004] at week 12. The difference in GLOESS between secukinumab and placebo was significant as early as one week after initiation of treatment. All key secondary endpoints were met. No new or unexpected safety findings were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This unique ultrasound study shows that apart from improving the signs and symptoms of PsA, IL-17A inhibition with secukinumab leads to a rapid and significant reduction of synovitis in PsA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov; NCT02662985.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab628","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T07:11:45Z","timestamp":1631517105000},"page":"1867-1876","source":"Crossref","is-referenced-by-count":38,"title":["Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5347-0060","authenticated-orcid":false,"given":"Maria Antonietta","family":"D\u2019Agostino","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Catholic University of Sacred Heart, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3"},{"name":"Deutsches Zentrum f\u00fcr Immuntherapie (DZI), Friedrich Alexander University of Erlangen-Nuremberg and Universit\u00e4tsklinikum Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"L\u00f3pez-Rdz","sequence":"additional","affiliation":[{"name":"Dermatol\u00f3gico Country, PSOAPS Psoriasis Clinical and Research Centre, Guadalajara, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Fazekas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Miskolci Semmelweis Hospital and University Teaching Hospital, Miskolci, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Burgos-Vargas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hospital General de Mexico, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Maldonado-Cocco","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz and Aut\u00f3noma University, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ghent University Hospital"},{"name":"VIB Inflammation Research Centre, Ghent University, Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Duggan","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Goyanka","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt Ltd, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-283X","authenticated-orcid":false,"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, and Amsterdam Rheumatology and Immunology Centre, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Gaillez","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2022051812483517800_keab628-B1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5435\/00124635-201201000-00004","article-title":"Psoriatic arthritis","volume":"20","author":"Day","year":"2012","journal-title":"J Am Acad Orthop Surg"},{"key":"2022051812483517800_keab628-B2","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64(Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022051812483517800_keab628-B3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051812483517800_keab628-B4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"2022051812483517800_keab628-B5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3899\/jrheum.140875","article-title":"Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA","volume":"41","author":"Coates","year":"2014","journal-title":"J Rheumatol"},{"key":"2022051812483517800_keab628-B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.reuma.2016.08.008","article-title":"Recommendations for the use of ultrasound and magnetic resonance in patients with spondyloarthritis, including psoriatic arthritis, and patients with juvenile idiopathic arthritis","volume":"14","author":"Uson","year":"2018","journal-title":"Reumatol Clin"},{"key":"2022051812483517800_keab628-B7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2010.138701","article-title":"How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography","volume":"70","author":"D'Agostino","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022051812483517800_keab628-B8","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D'Agostino","year":"2017","journal-title":"RMD Open"},{"key":"2022051812483517800_keab628-B9","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2014-206971","article-title":"EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice","volume":"74","author":"Mandl","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2022051812483517800_keab628-B10"},{"key":"2022051812483517800_keab628-B11","first-page":"848","article-title":"The OMERACT Ultrasound Group: status of current activities and research directions","volume":"34","author":"Wakefield","year":"2007","journal-title":"J Rheumatol"},{"key":"2022051812483517800_keab628-B12","doi-asserted-by":"crossref","first-page":"e000723","DOI":"10.1136\/rmdopen-2018-000723","article-title":"Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"2022051812483517800_keab628-B13","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1016\/S2665-9913(20)30036-9","article-title":"Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study","volume":"2","author":"McInnes","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2022051812483517800_keab628-B14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kez420","article-title":"Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5","volume":"59","author":"van der Heijde","year":"2020","journal-title":"Rheumatology"},{"key":"2022051812483517800_keab628-B15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"2022051812483517800_keab628-B16","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/annrheumdis-2015-207709","article-title":"Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study","volume":"75","author":"D'Agostino","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022051812483517800_keab628-B17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jclinepi.2003.05.002","article-title":"Null bar and null zone are better than the error bar to compare group means in graphs","volume":"57","author":"Boers","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2022051812483517800_keab628-B18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022051812483517800_keab628-B19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2022051812483517800_keab628-B20","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022051812483517800_keab628-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab628\/41428543\/keab628.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1867\/43750537\/keab628.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/1867\/43750537\/keab628.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T08:49:23Z","timestamp":1652863763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/1867\/6370966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,16]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab628","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,9,16]]}}}